Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Capital Expenditures (2016 - 2025)

Wave Life Sciences' Capital Expenditures history spans 11 years, with the latest figure at -$1000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 101.16% year-over-year to -$1000.0; the TTM value through Dec 2025 reached $718000.0, down 23.45%, while the annual FY2025 figure was $718000.0, 23.45% down from the prior year.
  • Capital Expenditures reached -$1000.0 in Q4 2025 per WVE's latest filing, down from $248000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $492000.0 in Q2 2022 to a low of -$1000.0 in Q4 2025.
  • Average Capital Expenditures over 5 years is $234600.0, with a median of $206000.0 recorded in 2022.
  • Peak YoY movement for Capital Expenditures: soared 1260.0% in 2022, then plummeted 101.16% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $15000.0 in 2021, then skyrocketed by 1260.0% to $204000.0 in 2022, then soared by 74.51% to $356000.0 in 2023, then tumbled by 75.84% to $86000.0 in 2024, then tumbled by 101.16% to -$1000.0 in 2025.
  • Per Business Quant, the three most recent readings for WVE's Capital Expenditures are -$1000.0 (Q4 2025), $248000.0 (Q3 2025), and $306000.0 (Q2 2025).